Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03676400 |
Recruitment Status :
Completed
First Posted : September 18, 2018
Last Update Posted : August 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Androgenic Alopecia | Other: conditioned media of umbilical cord blood-derived stem cells Other: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 84 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Product group / Control(placebo) group |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia |
Actual Study Start Date : | October 2, 2018 |
Actual Primary Completion Date : | July 22, 2019 |
Actual Study Completion Date : | July 24, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: NGF-574H
NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss. NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks. |
Other: conditioned media of umbilical cord blood-derived stem cells
Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
Other Name: NGF-574H |
Placebo Comparator: placebo
Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
|
Other: Placebo
Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells |
- Change in mean total hair density (hair/cm2) [ Time Frame: 0, 6, 12 and 24 weeks ]
- The hair density by phototrichogram for 24 weeks application, in comparison to initial value (baseline) and/or placebo product.
- Measurement of hair density by phototrichogram (Canfield): change in mean total hair density (hair/cm^2)
- Statistical analysis: Time and product effects (p<0.05)
- Compare visual assessment before and after cosmetic treatment [ Time Frame: 0, 6, 12 and 24 weeks ]Visual Assessment using the clinical picture by an investigator: 7 point score (-3 to 3) Visual assessment by a subject (Self-Assessment): 7 point score (-3 to 3)
- Change in mean Telogen hair density [ Time Frame: 0, 6, 12 and 24 weeks ]Measurement of telogen hair density, in comparison to initial value (baseline) and/or placebo product.
- Change in mean Anagen hair density [ Time Frame: 0, 6, 12 and 24 weeks ]Measurement of anagen hair density, in comparison to initial value (baseline) and/or placebo product.
- Change in hair growth speed [ Time Frame: 0, 6, 12 and 24 weeks ]Measurement of hair growth speed, in comparison to initial value (baseline) and/or placebo product.
- Change in hair diameter [ Time Frame: 0, 6, 12 and 24 weeks ]Measurement of hair diameter, in comparison to initial value (baseline) and/or placebo product. Measure hair diameter using electronic outside micrometer.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Origin: Asian (Korean)
- Age: adult from 18 to 60 years old
- Sex: female (minimum 70) and male
- Understanding of the language spoken in the research center: subjects able to read the documents they are presented with and to hold to what they are explained.
- Social cover: subjects having medical coverage
- Subjects whose state of health, at the moment of inclusion, (auto-questionnaires and medical examinations for the recruitment, selection and inclusion), are compatible with this type of study.
- Subjects can be pursuit and observation during the study period.
-
Subjects have a "hair loss grade" as below criteria:
- BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3)
- For female: Ludwig grade: Ⅰ to Ⅱ
- For male: Norwood-Hamilton grade: III to IV
- Hair density by phototrichogram: 60 to 190 hair/cm2
- Telogen hair ≥ 5%
- Subject with hair length ≥3cm in the vertex region and intending to keep this minimum length during the whole study period.
- Subject accepting the constraints of the phototrichogram technique, i.e. agreeing to have 1 shaved zone of 1.5cm2 on the scalp.
- Subject agreeing not to apply any topical treatment (other than the investigational product) or take any oral product or nutritional supplementation, or have any diet known to improve scalp and/or hair qualities or reduce hair loss during the whole study period.
- Subject agreeing to use a neutral shampoo (subject's own shampoo)
- Subject agrees to have a tattoo on the scalp on phototrichogram evaluation area.
- Subject presenting preferably with chestnut brown, dark or black hair (in order to avoid problems of contrast)
Exclusion Criteria:
- Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency.
- Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner.
- Subject who cannot be contacted in case of emergency.
- Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method.
- Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia.
- Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study.
- Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening)
- Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...)
- Subject following a long period (>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)
- Subject following a short period (<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period.
- Subject having a immunosuppressive and/or corticoids treatment during the 4 weeks preceding the screening period
- Subject having dyed, bleached hair or with a permanent wave prior to study start.
- Subject who have been exposed to excessive or intensive UV light (natural or artificial) prior to the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03676400
Korea, Republic of | |
Dankook University Hospital | |
Cheonan, Chung Nam, Korea, Republic of, 31116 |
Principal Investigator: | Byungcheol PARK, MD | Dankook University |
Responsible Party: | Medipost Co Ltd. |
ClinicalTrials.gov Identifier: | NCT03676400 |
Other Study ID Numbers: |
MP-CM-001 |
First Posted: | September 18, 2018 Key Record Dates |
Last Update Posted: | August 12, 2019 |
Last Verified: | August 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
mesenchymal stem cells conditioned media NGF-574H hair growth |
androgenic alopecia paracrine factors umbilical cord blood |
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |